Industry: Healthcare Region: UK Deal price: $1 million Deal Method: Equity financing
Brief introduction:
The company is a Cambridge-based biotechnology contract research and drug development company that operates a hybrid business model.
This model can generate revenue through its services business while developing the following business: an internal drug discovery pipeline. The company has an excellent track record of delivering drug candidates. It has a world-class discovery team, and its unmatched track record shows that for the past six years, it has delivered an average of one drug candidate per year on behalf of its clients.
Revenue in 2019 was approximately £6 million, with 83% of sales coming from a strongly growing industrial customer base that is now the core of the business.